Hypertension is known as a cause of endothelial cell damage and it activates humoral immunity. Therefore, it may modulate the anti-beta2-glycoprotein I antibody (aβGPI) to commit for thrombosis. To elucidate the relation between aβGPI and hypertension in cerebral ischemia, the blood aβGPI level was examined in healthy subjects, hypertensive subjects, and patients with cerebral ischemia with and without hypertension, respectively. The results showed that the blood aβGPI level increased in cerebral ischemia patients with hypertension rather than hypertensive subjects, and patients without hypertension rather than healthy individuals. However, the blood aβGPI level showed no difference between healthy individuals and hypertensive subjects, nor cerebral ischemia patients with and without hypertension. The serum globulin level did not change among them. Therefore, aβGPI displays a vital role for cerebral ischemia in both hypertensive and normotensive subjects. An activation of humoral immunity involving aβGPI warrants further investigation in cerebral ischemia.
1. Chen WH, Kao YF, Lan MY, et al. A perturbation of antithrombin III and protein coupling associates with an increase of anti-beta2-glycoprotein I antibody in non-APS cerebral ischemia. Blood Coag Fibrinolysis2002;13:703-703.
2.
2. Nagaraja D, Christopher R, Manjari T. Anticardiolipin antibodies in ischemic stroke in the young: Indian experience. J Neurol Sci1997; 150:137-137.
3.
3. Montalban J, Codina A, Ordi J, et al. Antiphospholipid antibodies in cerebral ischemia. Stroke1991;22:750-750.
4.
4. Chen WH, Liu JS. An unusual increase of blood anti-beta 2-glycoprotein-I antibody but not antiphospholipid antibody in cerebral ischemia. Angiology2001;52:149-149.
5.
5. Heinzlef O, Abuaf N, Cohen A, et al. Recurrent stroke and vascular events in elderly patients with anticardiolipin antibodies: A prospective study. J Neurol2001;248:373-373.
6.
6. Granel F, de Maistre E, Challier B, et al. Ischemic stroke in young patients and/or livedo: Is it important to look for anti-beta 2-glycoprotein I antibodies? [Fre]. Rev Med Interne1998;19:709-709.
7.
7. Ross R. Atherosclerosis-an inflammatory disease. N Engl JMed1999;340:115-115.
8.
8. Fu ML. Abnormal immune system and hypertension: Where are we?Ann Med1995;27:671-671.
9.
9. Chen WH, Lan MY, Chang YY, et al. The prevalence of protein C, protein S and antithrombin III deficiency in non-APS/SLE Chinese adults with noncardiac cerebral sichemia. Clin Appl Thromb/Hemost2003;9:155-155.
10.
10. Chen WH, Chang YY, Chou MS, et al. The lipoprotein profile of young adults with cerebral atherosclerosis. Southeast Asian J Trop Med Publ Health1996;27:178-178.
11.
11. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med2002;346:752-752.
12.
12. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythrematosus. Arthritis Rheum1982;25:1271-1271.
13.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythrematosus. Arthritis Rheum1997; 40:1725-1725.
14.
14. Frostegard J, Wu R, Gillis-Haegerstrand C, et al. Antibodies to endothelial cells in borderline hypertension. Circulation1998;98:1092-1092.
15.
15. Fiallo P, Tomasina C, Clapasson A, et al. Antibodies to beta(2)-glycoprotein I in ischemic stroke. Cerebrovasc Dis2000; 10:293-293.
16.
16. Valdes-Macho E, Cabiedes J, Villa AR, et al. Anticardiolipin and anti-beta2-glycoprotein-I antibodies in hypertensive disorders of pregnancy. Arch Med Res2002;33:460-460.
17.
17. Sherer Y, Tenenbaum A, Praprotnik S, et al. Autoantibodies to cardiolipin and beta-2-glycoprotein-I in coronary artery disease patients with and without hypertension. Cardiology2002;97:2-2.
18.
18. Arnett FC, Thiagarajan P, Ahn C, et al. Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. Arthritis Rheum1999;42:268-268.
19.
19. Blann AD, Tse W, Maxwell SJ, Waite MA. Increased levels of the soluble adhesion molecule E-selectin in essential hypertension. J Hypertens1994;12:925-925.
20.
20. Felmeden DC, Spencer CG, Belgore FM, et al. Endothelial damage and angiogenesis in hypertensive patients: Relationship to cardiovascular risk factors and risk factor management. Am J Hypertens2003; 16:11-11.
21.
21. Chen WH, Lan MY, Chang YY, et al. The thyrocalcitrophic hormones and related minerals in young untreated normoreninergic hypertensive women with noncardiac cerebral ischemia. Acta Neurol Taiwanica2001;10:21-21.
22.
22. Rosskopf D, Hartung K, Hense J, et al. Enhanced immunoglobulin formation of immortalized B cells from hypertensive patients. Hypertension1995;26:432-432.
23.
23. Khraibi AA. Association between disturbances in the immune system and hypertension. Am J Hypertens1991;4:635-635.
24.
24. Suryaprabha P, Padma T, Brahmaji-Rao U. Increased serum IgG levels in essential hypertension. Immunol Lett1984;8:143-143.
25.
25. Fannon LD, Braylan RC, Phillips MI. Alterations of lymphocyte populations during development in the spontaneously hypertensive rat. J Hypertens1992;10:629-629.
26.
26. Fu ML. Do immune system changes have a role in hypertension?J Hypertens1995;13:1259-1259.
27.
27. Tomiyama H, Kimura Y, Mitsuhashi H, et al. Relationship between endothelial function and fibrinolysis in early hypertension. Hypertension1998;31:321-321.
28.
28. Manfredi AA, Rovere P, Heltai S, et al. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I. Arthritis Rheum1998;41:215-215.
29.
29. Farsi A, Domeneghetti MP, Fedi S, et al. High prevalence of anti-beta2 glycoprotein I antibodies in patients with ischemic heart disease. Autoimmunity1999;30:93-93.
30.
30. Sherer Y, Tenenbaum A, Praprotnik S, et al. Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-I, and oxidized LDL antibodies. Cardiology2001;95:20-20.
31.
31. Ruihua Wu, Ulf de Faire, Carola Lemne, et al. Autoantibodies to oxLDL are decreased in individuals with borderline hypertension. Hypertension1999;33:53-53.
